Cite
HARVARD Citation
Pautier, P. et al. (2022). Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet oncology. 23 (8), pp. 1044-1054. [Online].